Composition comprising dutasteride
AssigneeChong Kun Dang Pharmaceutical Corp.
InventorsTae Hyun Park, Ki Seong Ko, So Hyun Park, Sang Myoung Noh, Jong Lae Lim
Life of this patent
Estimating the term…
Abstract
A composition of the present invention relates to a composition comprising dutasteride, wherein said composition may maintain a constant concentration of dutasteride in blood and continuously release a drug thereof for a long period of time while not precipitating dutasteride in a solid form when being administered into the human body, and also has an excellent safety without causing local irritations in an administration site.
Claims12
A parenteral composition comprising dutasteride, optical isomers thereof or pharmaceutically acceptable salts thereof, lipid and an organic solvent, wherein:
- the lipid is selected from the group consisting of tocopherol, tocopherol acetate, pharmaceutically acceptable salts thereof and mixtures thereof and the lipid is present in an amount of 13 to 70 wt % with regard to the total weight of the composition.
A method for preventing or treating benign prostatic hyperplasia or androgenetic alopecia by administering a therapeutically effective dose of a composition comprising dutasteride, optical isomers thereof or pharmaceutically acceptable salts thereof, lipid and an organic solvent to a subject in need of treatment, wherein:
- the lipid is selected from the group consisting of tocopherol, tocopherol acetate, pharmaceutically acceptable salts thereof and mixtures thereof and the lipid is present in an amount of 13 to 70 wt % with regard to the total weight of the composition;
- and
- the composition is administered through an injection.
A parenteral composition comprising dutasteride, optical isomers thereof or pharmaceutically acceptable salts thereof;
- tocopherol;
- N-methyl-2-pyrrolidone and dimethyl sulfoxide,
- wherein tocopherol is present in an amount of 13 to 70 wt % with regard to the total weight of the composition.
A method for preventing or treating benign prostatic hyperplasia or androgenetic alopecia by administering a therapeutically effective dose of a composition comprising dutasteride, optical isomers thereof or pharmaceutically acceptable salts thereof;
- tocopherol;
- N-methyl-2-pyrrolidone and dimethyl sulfoxide,
- wherein tocopherol is present in an amount of 13 to 70 wt % with regard to the total weight of the composition, and wherein the composition is administered through an injection.
Dependencies are inferred from the claim text.